Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
News Medical1d
Shift Bioscience establishes North American facilities to expand capabilities of AI-powered virtual cell technology
Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the establishment of a new North American team and facilities to advance development ...
News Medical3d
AI predicts preterm birth risk with 82% accuracy
Researchers used machine learning models to predict preterm birth risk, identifying linear SVMs as the most accurate, with ...